13D Filing: Gl Partners Capital Management Ltd and Sciclone Pharmaceuticals Inc (SCLN)

Page 5 of 11

Page 5 of 11 – SEC Filing

CUSIP No. 80862K104
1.

NAME OF REPORTING PERSON:

GL Capital Management GP Limited

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨
(b) ¨

3.

SEC USE ONLY

4.

SOURCE OF FUNDS

AF

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e): ¨
6.

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON

WITH
7.

SOLE VOTING POWER

4,750,116

8.

SHARED VOTING POWER

0

9.

SOLE DISPOSITIVE POWER

4,750,116

10.

SHARED DISPOSITIVE POWER

0

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,750,116

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES

¨

13.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

9.2%1

14.

TYPE OF REPORTING PERSON

CO

1. Percentage calculated based on 51,790,347
shares of Common Stock issued and outstanding as of May 26, 2017, as provided by the Company.

5

Follow Sciclone Pharmaceuticals Inc (NASDAQ:SCLN)

Page 5 of 11